Salarius Pharmaceuticals To Rebrand As Decoy Therapeutics Following Combination, Changes NASDAQ Ticker Symbol To DCOY

The combined Company will move forward as Decoy Therapeutics, Inc. and trade on the NASDAQ Stock Market under the ticker "DCOY" effective in early January 2026

Company to focus on advancing lead antiviral programs, expanding platform validation and achieving multiple data milestones

Strategic 2026 roadmap designed to accelerate development, expand pipeline breadth, and drive long-term shareholder value

HOUSTON, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) today announced that in connection with its recent combination with Decoy Therapeutics Inc. (Decoy), the Company intends to change its corporate name to Decoy Therapeutics Inc. and its NASDAQ ticker symbol to DCOY.

The planned name and ticker change mark a pivotal step in the Company's transformation into a platform-driven biotechnology company focused on novel peptide-conjugate therapeutics with applications across viral diseases and oncology.

The Company expects the name and ticker symbol change to become effective in early January 2026. The Company will continue to trade under the existing symbol SLRX until the effective date. The Company's transfer agent will remain unchanged. Stockholder approval was not required to take any specific action with respect to the corporate name change or new ticker symbol. The corporate name change and new ticker symbol will not impact the Company's operations. As previously announced Decoy's senior management team joined by Salarius's finance team will lead the new Company's operations.